Hester Biosciences Limited has informed the Exchange regarding Board meeting held on August 01, 2025.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.1 pts more than Nifty Microcap 250 and 13.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported its Q1 FY26 results. On a standalone basis, revenue from operations declined ~14% YoY to INR 634.90 million, largely due to a 33% drop in the Animal Healthcare division caused by delays in government immunization programs for PPR and Lumpy Skin Disease vaccines. Standalone PAT fell ~7% to INR 78.38 million and EPS stood at INR 9.21 vs INR 9.91. The Poultry Healthcare division grew ~2% YoY supported by strong demand for Newcastle Disease and Marek's Disease vaccines. On a consolidated basis, revenue rose ~2% to INR 841.05 million, while PAT surged 131% to INR 172.96 million, driven mainly by a sharp turnaround at Hester Africa (net profit of INR 55.02 million versus a loss of INR 50 million a year ago). Consolidated EBITDA margin expanded from 24% to 31%. The company also restated prior period segment information after merging its Petcare business into Animal Healthcare.
Mixed quarter for shareholders — standalone performance was weak due to government tender timing delays, but consolidated profit jumped sharply on the back of Hester Africa's recovery. Investors will likely focus on the management's guidance that the delayed immunization programs will roll out in subsequent quarters, which could support a recovery in standalone numbers.